FIELD: biotechnology.
SUBSTANCE: invention refers specifically to a method of treating an individual in need of elongation of telomeres by increasing the expression level of Zscan4, and can be used in medicine.
EFFECT: patient's contact with nucleic acid coding Zscan4 enables the effective therapy of diseases caused by telomere shortening, chromosomal or karyotypic aberration.
56 cl, 19 dwg, 1 tbl, 19 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND LIBRARIES CONTAINING RECOMBINANT POLYNUCLEOTIDES ENCODING T-CELL RECEPTORS AND METHODS FOR USING RECOMBINANT T-CELL RECEPTORS | 2017 |
|
RU2752528C2 |
| NOVEL EUKARYOTIC CELLS AND METHODS FOR PREPARING THEM FOR RECOMBINANT EXPRESSION OF A PRODUCT OF INTEREST | 2014 |
|
RU2720525C2 |
| MODIFIED FACTOR IX, AS WELL AS COMPOSITIONS, METHODS AND OPTIONS FOR THE USE OF GENE TRANSFER INTO CELLS, ORGANS AND TISSUE | 2016 |
|
RU2811445C2 |
| CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | 2014 |
|
RU2727447C2 |
| RECOVERED NUCLEIC ACID WHICH CODES FVIII-BDD-BASED FUSION PROTEIN AND HETEROLOGOUS SIGNAL PEPTIDE, AND USE THEREOF | 2022 |
|
RU2818229C2 |
| ANTIBODIES AGAINST HUMAN VSIG4 AND APPLICATION THEREOF | 2019 |
|
RU2776638C1 |
| CHIMERIC ANTIGEN RECEPTORS AIMED AT PSCA | 2016 |
|
RU2759879C2 |
| BISPECIFIC ANTIBODIES TO HUMAN CD20/HUMAN TRANSFERRIN RECEPTOR AND METHODS FOR THEIR USE | 2016 |
|
RU2753390C1 |
| COMBINATION THERAPY BASED ON T-CELL-ACTIVATING BISPECIFIC ANTIGEN-BINDING MOLECULES AGAINST CD3 AND FOLATE RECEPTOR 1 (FOLR1) AND ANTAGONISTS BINDING TO PD-1 AXIS | 2015 |
|
RU2753902C2 |
| CD123-SPECIFIC CHIMERIC ANTIGENIC RECEPTORS FOR CANCER IMMUNOTHERAPY | 2015 |
|
RU2727290C2 |
